Clinical trials: Gene Mutations
CRC, Colorectal Cancer
An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.
This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS…
- Trial name
- NCT06985316
- Testing
- Tunlametinib combined with Fruquintinib
- Volunteers
- 34 people
- Sponsor
- Liu Huang
Colon Cancer
Multi Parametric Test Predicting the Risk of Colorectal Neoplasia Recurrence
This project is dedicated to identify the patients with possible higher risk of adenoma recurrence who should have follow-up colonoscopy in yearly interval.
- Trial name
- NCT03434925
- Testing
- Multi-targeted next generation sequencing
- Where
- Czechia
- Volunteers
- 200 people
- Sponsor
- Military University Hospital, Prague
Carcinoma, Non-Small-Cell Lung
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
The primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2 dose (RP2D) when administered as first line (1L)…
- Trial name
- NCT05469178
- Testing
- Bemcentinib, Pembrolizumab, Pemetrexed
- Where
- 34 sites in United States, France and 5 more
- Volunteers
- 26 people
- Sponsor
- BerGenBio ASA
Advanced Non Small Cell Lung Cancer
Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC
The aim of the study was to investigate the efficacy of Toripalimab Combined with Double Platinum Based Chemotherapy for Initially Unresectable Non-driver Gene Mutation Non-small Cell Lung Cancer.
- Trial name
- TOGATHER (NCT04144608)
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yongchang Zhang
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Cancer Prevention in Women With a BRCA Mutation
This study aims to develop a follow-up telephone-based genetic counselling (FTGC) intervention for women with a BRCA1 or BRCA2 mutation who have received genetic counseling in the past.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02225015
- Testing
- Follow-up Telephone Genetic Counselling
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Women's College Hospital
Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A…
- Conditions
- Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT05326516
- Testing
- Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 11 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Syndax Pharmaceuticals
Advanced NSCLC
AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
This study is conducted to assess the safety, tolerability and preliminary efficacy of AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT03127449
- Testing
- Alflutinib
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Advanced NSCLC
Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations
This is a phase II, Single-arm,Open-label Study evaluating the safety and efficacy of CT053PTSA in Advanced Solid Tumors With MET Exon 14 Skipping Mutations
- Trial name
- NCT04992858
- Testing
- CT053PTSA
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation
Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
This randomized pilot clinical trial studies a nanoemulsion formulation of curcumin in reducing inflammatory changes in breast tissue in obese women at high risk for breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ
- Trial name
- NCT01975363
- Testing
- curcumin, Biomarker analysis, Assessment of Dietary Intake
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer
Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation
This research trial studies genetic mutations in blood and tissue samples to see if they can be used to predict treatment response in patients with locally advanced rectal cancer undergoing chemoradiation.
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer
- Trial name
- NCT02132858
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Fox Chase Cancer Center
GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Gastrointestinal stromal tumors (GISTs) are mostly driven by c-kit or PDGFRA mutations, and commonly occur in the stomach and small intestine.
- Trial name
- NCT07559864
- Testing
- physician-selected treatment, Regorafenib + Envafolimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jian Li
PEComa, Malignant, TSC1
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a…
- Conditions
- PEComa, Malignant, TSC1, TSC2, mTOR Pathway Abberation
- Trial name
- NCT03817515
- Testing
- ABI-009
- Sponsor
- Aadi Bioscience, Inc.
Duodenal Diseases
Endoscopic Characteristics of Duodenal and Ampullary Lesions
The purpose is to investigate whether polyps that look different at endoscopy, have formed via different mutations and have different risks of turning into cancer.
- Trial name
- DUO/AMP-LST (NCT01556399)
- Testing
- Tissue Sampling
- Where
- Australia
- Volunteers
- 350 people
- Sponsor
- Professor Michael Bourke
Metastatic NSCLC - Non-Small Cell Lung Cancer
Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.
To assess safety and efficacy of amivantamab plus monochemotherapy in terms of ORR, PFS and OS in subjects with EGFR exon20 insertion mutations metastatic non-small cell lung cancer unfit for platinum-based chemotherapy.
- Trial name
- AMICUTE (NCT07392658)
- Testing
- Amivantamab
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Fondazione Ricerca Traslazionale
Myelodysplastic Syndromes
An European Platform for Translational Research in Myelodysplastic Syndromes
Rationale Myelodysplastic syndromes (MDS) are rare cancers with unmet medical needs. Study of MDS has been rapidly transformed by genome characterization.
- Trial name
- NCT04174547
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 8,670 people
- Sponsor
- Istituto Clinico Humanitas
Homozygous Familial Hypercholesterolemia
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
This is an early phase 1, open-label, single-center, dose-escalation, pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in homozygous familial hypercholesterolemia (HoFH) patients with LDLR…
- Trial name
- NCT06125847
- Testing
- NGGT006
- Where
- China
- Volunteers
- 21 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT05379985
- Testing
- RMC-6236
- Where
- 21 sites in United States
- Volunteers
- 754 people
- Sponsor
- Revolution Medicines, Inc.
NCOR Gene Mutations, Spironolactone
Spironolactone Improved Children With Gene Mutations Related to NCOR
MECP2, a key transcriptional regulator, has been shown to interact with the NCOR1/2 complex to modulate gene expression. Specifically, MECP2 recruits the NCOR complex to specific genomic loci, facilitating histone deacetylation…
- Conditions
- NCOR Gene Mutations, Spironolactone, ASD
- Trial name
- NCT06678685
- Testing
- .spironolactone
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Qilu Hospital of Shandong University
Brain Arterial Disease
Liquid Biopsies for the Detection of Somatic Mutations in bAVMs
"Personalized medicine has revolutionized patient care, particularly in oncology. Brain arteriovenous malformations (bAVMs) are abnormal vessels located on the surface of the brain or within the brain parenchyma, causing abnormal…
- Trial name
- BioMAV (NCT06494358)
- Testing
- liquid biopsies and surgery specimen analysis
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Parkinson Disease
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease…
- Trial name
- NCT04127578
- Testing
- LY3884961, Methylprednisolone, Sirolimus
- Where
- 15 sites in United States, Israel
- Volunteers
- 32 people
- Sponsor
- Prevail Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.